Published in IEEE Eng Med Biol Mag on July 27, 2010
Parametric imaging of the local attenuation coefficient in human axillary lymph nodes assessed using optical coherence tomography. Biomed Opt Express (2012) 1.12
Point-of-care and point-of-procedure optical imaging technologies for primary care and global health. Sci Transl Med (2014) 1.08
Optical coherence tomography for advanced screening in the primary care office. J Biophotonics (2013) 1.05
Real-time Imaging of the Resection Bed Using a Handheld Probe to Reduce Incidence of Microscopic Positive Margins in Cancer Surgery. Cancer Res (2015) 0.90
Three-dimensional optical coherence tomography for optical biopsy of lymph nodes and assessment of metastatic disease. Ann Surg Oncol (2012) 0.89
Sonification of optical coherence tomography data and images. Opt Express (2010) 0.81
Intraoperative optical coherence tomography for assessing human lymph nodes for metastatic cancer. BMC Cancer (2016) 0.81
Optical coherence tomography for rapid tissue screening and directed histological sectioning. Anal Cell Pathol (Amst) (2012) 0.76
Live volumetric (4D) visualization and guidance of in vivo human ophthalmic surgery with intraoperative optical coherence tomography. Sci Rep (2016) 0.75
Investigation of optical coherence micro-elastography as a method to visualize micro-architecture in human axillary lymph nodes. BMC Cancer (2016) 0.75
Review of intraoperative optical coherence tomography: technology and applications [Invited]. Biomed Opt Express (2017) 0.75
Optical coherence tomography. Science (1991) 57.87
Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol (2003) 11.09
The sentinel node in breast cancer--a multicenter validation study. N Engl J Med (1998) 8.48
Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med (2009) 5.36
Imaging of lymph flow in breast cancer patients after microdose administration of a near-infrared fluorophore: feasibility study. Radiology (2008) 4.15
Optical coherence tomography: a review of clinical development from bench to bedside. J Biomed Opt (2007) 3.18
Buffered Fourier domain mode locking: Unidirectional swept laser sources for optical coherence tomography imaging at 370,000 lines/s. Opt Lett (2006) 3.13
Optical coherence tomography: an emerging technology for biomedical imaging and optical biopsy. Neoplasia (2000) 2.84
Rapid-scanning forward-imaging miniature endoscope for real-time optical coherence tomography. Opt Lett (2004) 2.38
Intraoperative evaluation of breast tumor margins with optical coherence tomography. Cancer Res (2009) 2.28
Sentinel lymph node mapping with type-II quantum dots. Methods Mol Biol (2007) 2.26
Ultrahigh-resolution optical coherence tomography with monochromatic and chromatic aberration correction. Opt Express (2008) 2.26
In vivo cellular optical coherence tomography imaging. Nat Med (1998) 2.15
New horizons for imaging lymphatic function. Ann N Y Acad Sci (2008) 2.00
Light scattering from cervical cells throughout neoplastic progression: influence of nuclear morphology, DNA content, and chromatin texture. J Biomed Opt (2003) 1.96
Optical coherence tomography: feasibility for basic research and image-guided surgery of breast cancer. Breast Cancer Res Treat (2004) 1.62
Infrared ray electronic endoscopy combined with indocyanine green injection for detection of sentinel nodes of patients with gastric cancer. Br J Surg (2004) 1.54
Influence of frozen-section analysis of sentinel lymph node and lumpectomy margin status on reoperation rates in patients undergoing breast-conservation therapy. J Am Coll Surg (2007) 1.48
Computational methods for analysis of human breast tumor tissue in optical coherence tomography images. J Biomed Opt (2006) 1.42
Intraoperative assessment of microsurgery with three-dimensional optical coherence tomography. Radiology (1998) 1.28
Infrared micro-spectral imaging: distinction of tissue types in axillary lymph node histology. BMC Clin Pathol (2008) 1.26
Automated algorithm for differentiation of human breast tissue using low coherence interferometry for fine needle aspiration biopsy guidance. J Biomed Opt (2008) 1.21
Optical biopsy of lymph node morphology using optical coherence tomography. Technol Cancer Res Treat (2005) 1.16
Light scattering from normal and dysplastic cervical cells at different epithelial depths: finite-difference time-domain modeling with a perfectly matched layer boundary condition. J Biomed Opt (2003) 1.15
Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer. J Clin Oncol (2008) 1.14
Refractive index of carcinogen-induced rat mammary tumours. Phys Med Biol (2006) 1.11
Needle-based refractive index measurement using low-coherence interferometry. Opt Lett (2007) 1.02
Optical imaging technology in minimally invasive surgery. Current status and future directions. Surg Endosc (1999) 1.00
Intraoperative evaluation of sentinel lymph nodes for metastatic breast carcinoma by imprint cytology. Mod Pathol (2002) 0.87
Intraoperative frozen section assessment of sentinel lymph nodes in the operative management of women with symptomatic breast cancer. World J Surg Oncol (2008) 0.85
Accuracy of imprint cytology for intraoperative diagnosis of sentinel node metastases in breast cancer. Ann Surg (2008) 0.85
Debilitating lymphedema of the upper extremity after treatment of breast cancer. Am J Clin Oncol (2002) 0.83
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol (2010) 4.69
Optical coherence tomography: a review of clinical development from bench to bedside. J Biomed Opt (2007) 3.18
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol (2009) 2.54
The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care Cancer (2010) 2.43
Intraoperative evaluation of breast tumor margins with optical coherence tomography. Cancer Res (2009) 2.28
Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol (2006) 2.28
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol (2014) 2.25
Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51. Leuk Lymphoma (2007) 2.20
Gas-phase databases for quantitative infrared spectroscopy. Appl Spectrosc (2004) 2.06
Optical micro-scale mapping of dynamic biomechanical tissue properties. Opt Express (2008) 2.02
Engineered microsphere contrast agents for optical coherence tomography. Opt Lett (2003) 1.91
Fourier transform light scattering of inhomogeneous and dynamic structures. Phys Rev Lett (2008) 1.90
Biomechanical properties of in vivo human skin from dynamic optical coherence elastography. IEEE Trans Biomed Eng (2009) 1.89
Optical coherence elastography of engineered and developing tissue. Tissue Eng (2006) 1.86
In vivo three-dimensional optical coherence elastography. Opt Express (2011) 1.84
Plasmon-resonant gold nanorods as low backscattering albedo contrast agents for optical coherence tomography. Opt Express (2006) 1.81
Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer (2008) 1.80
Spectroscopic spectral-domain optical coherence microscopy. Opt Lett (2006) 1.77
Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol (2006) 1.76
Nonlinear interferometric vibrational imaging. Phys Rev Lett (2004) 1.75
Imaging magnetically labeled cells with magnetomotive optical coherence tomography. Opt Lett (2005) 1.73
Phase-resolved magnetomotive OCT for imaging nanomolar concentrations of magnetic nanoparticles in tissues. Opt Express (2008) 1.67
In vivo magnetomotive optical molecular imaging using targeted magnetic nanoprobes. Proc Natl Acad Sci U S A (2010) 1.65
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol (2008) 1.65
Noninvasive in vivo optical detection of biofilm in the human middle ear. Proc Natl Acad Sci U S A (2012) 1.63
Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol (2010) 1.61
The prevalence of weight concerns in a smoking abstinence clinical trial. Addict Behav (2005) 1.60
Computational adaptive optics for broadband optical interferometric tomography of biological tissue. Proc Natl Acad Sci U S A (2012) 1.57
Handheld optical coherence tomography scanner for primary care diagnostics. IEEE Trans Biomed Eng (2010) 1.56
Multimodal biomedical imaging with asymmetric single-walled carbon nanotube/iron oxide nanoparticle complexes. Nano Lett (2007) 1.55
Magnetomotive nanoparticle transducers for optical rheology of viscoelastic materials. Opt Express (2009) 1.53
High-resolution three-dimensional imaging of biofilm development using optical coherence tomography. J Biomed Opt (2006) 1.46
Acoustomotive optical coherence elastography for measuring material mechanical properties. Opt Lett (2009) 1.45
Dynamic spectral-domain optical coherence elastography for tissue characterization. Opt Express (2010) 1.44
Spectroscopic optical coherence elastography. Opt Express (2010) 1.43
Computational methods for analysis of human breast tumor tissue in optical coherence tomography images. J Biomed Opt (2006) 1.42
Full-range k-domain linearization in spectral-domain optical coherence tomography. Appl Opt (2011) 1.41
Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol (2008) 1.41
A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer (2003) 1.41
Microscopic imaging and spectroscopy with scattered light. Annu Rev Biomed Eng (2010) 1.41
Speckle reduction by I-divergence regularization in optical coherence tomography. J Opt Soc Am A Opt Image Sci Vis (2005) 1.41
A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer (2010) 1.41
Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer (2005) 1.40
Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol (2004) 1.40
Transgenic expression of {alpha}7{beta}1 integrin maintains muscle integrity, increases regenerative capacity, promotes hypertrophy, and reduces cardiomyopathy in dystrophic mice. Am J Pathol (2005) 1.37
Comparative performance analysis of time-frequency distributions for spectroscopic optical coherence tomography. Appl Opt (2005) 1.35
Three-dimensional optical coherence tomography of the embryonic murine cardiovascular system. J Biomed Opt (2006) 1.33
Stabilization of continuum generation from normally dispersive nonlinear optical fibers for a tunable broad bandwidth source for optical coherence tomography. Opt Lett (2007) 1.32
Inverse scattering for optical coherence tomography. J Opt Soc Am A Opt Image Sci Vis (2006) 1.32
Real-time in vivo computed optical interferometric tomography. Nat Photonics (2013) 1.31
Resonant acoustic spectroscopy of soft tissues using embedded magnetomotive nanotransducers and optical coherence tomography. Phys Med Biol (2010) 1.30
Optical frequency up-conversion by supercontinuum-free widely-tunable fiber-optic Cherenkov radiation. Opt Express (2009) 1.30
Scalar generalized nonlinear Schrödinger equation-quantified continuum generation in an all-normal dispersion photonic crystal fiber for broadband coherent optical sources. Opt Express (2010) 1.30
Non-invasive optical interferometry for the assessment of biofilm growth in the middle ear. Biomed Opt Express (2010) 1.29
Projected index computed tomography. Opt Lett (2003) 1.29
Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer (2009) 1.28
Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol (2004) 1.28
Nonparaxial vector-field modeling of optical coherence tomography and interferometric synthetic aperture microscopy. J Opt Soc Am A Opt Image Sci Vis (2007) 1.25
Autofocus algorithm for dispersion correction in optical coherence tomography. Appl Opt (2003) 1.25
Digital algorithm for dispersion correction in optical coherence tomography for homogeneous and stratified media. Appl Opt (2003) 1.24
Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain (2002) 1.24
Near-infrared dyes as contrast-enhancing agents for spectroscopic optical coherence tomography. Opt Lett (2004) 1.23
Localized waveguide formation in germanosilicate fiber transmitting femtosecond IR pulses. J Opt Soc Am B (2008) 1.22
Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc (2006) 1.20
Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol (2009) 1.20
Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention. Mayo Clin Proc (2007) 1.19
Inverse scattering for frequency-scanned full-field optical coherence tomography. J Opt Soc Am A Opt Image Sci Vis (2007) 1.19
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol Oncol (2009) 1.18
Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer. Clin Colorectal Cancer (2006) 1.18
Cross-correlation-based image acquisition technique for manually-scanned optical coherence tomography. Opt Express (2009) 1.17
Imaging gold nanorods in excised human breast carcinoma by spectroscopic optical coherence tomography. J Mater Chem (2009) 1.17
Endpoints in phase II trials for advanced non-small cell lung cancer. J Thorac Oncol (2010) 1.16
Optical biopsy of lymph node morphology using optical coherence tomography. Technol Cancer Res Treat (2005) 1.16
Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials. Cancer (2009) 1.15
Functional optical coherence tomography for detecting neural activity through scattering changes. Opt Lett (2003) 1.15
Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. J Clin Oncol (2006) 1.14
Dual-spectrum laser source based on fiber continuum generation for integrated optical coherence and multiphoton microscopy. J Biomed Opt (2009) 1.14
High speed nonlinear interferometric vibrational analysis of lipids by spectral decomposition. Anal Chem (2010) 1.13
High-spectral-resolution coherent anti-Stokes Raman scattering with interferometrically detected broadband chirped pulses. Opt Lett (2006) 1.13
Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer. J Thorac Oncol (2009) 1.12
Use of DNA and peptide nucleic acid molecular beacons for detection and quantification of rRNA in solution and in whole cells. Appl Environ Microbiol (2003) 1.12